Investigation of leucine‐rich repeat kinase 2
Authors:
Open Access
- 29 December 2008
- journal article
- Published by Wiley in The FEBS Journal
- Vol. 276 (2) , 466-478
Abstract
Mutations in leucine‐rich repeat kinase 2 (LRRK2) comprise the leading cause of autosomal dominant Parkinson’s disease, with age of onset and symptoms identical to those of idiopathic forms of the disorder. Several of these pathogenic mutations are thought to affect its kinase activity, so understanding the roles of LRRK2, and modulation of its kinase activity, may lead to novel therapeutic strategies for treating Parkinson’s disease. In this study, highly purified, baculovirus‐expressed proteins have been used, for the first time providing large amounts of protein that enable a thorough enzymatic characterization of the kinase activity of LRRK2. Although LRRK2 undergoes weak autophosphorylation, it exhibits high activity towards the peptidic substrate LRRKtide, suggesting that it is a catalytically efficient kinase. We have also utilized a time‐resolved fluorescence resonance energy transfer (TR‐FRET) assay format (LanthaScreen™) to characterize LRRK2 and test the effects of nonselective kinase inhibitors. Finally, we have used both radiometric and TR‐FRET assays to assess the role of clinical mutations affecting LRRK2’s kinase activity. Our results suggest that only the most prevalent clinical mutation, G2019S, results in a robust enhancement of kinase activity with LRRKtide as the substrate. This mutation also affects binding of ATP to LRRK2, with wild‐type binding being tighter (Km,app of 57 μm) than with the G2019S mutant (Km,app of 134 μm). Overall, these studies delineate the catalytic efficiency of LRRK2 as a kinase and provide strategies by which a therapeutic agent for Parkinson’s disease may be identified.Keywords
This publication has 31 references indexed in Scilit:
- Phosphorylation of 4E‐BP by LRRK2 affects the maintenance of dopaminergic neurons in DrosophilaThe EMBO Journal, 2008
- The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular AutophosphorylationJournal of Biological Chemistry, 2008
- The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2Journal of Neuroscience, 2008
- The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubulesJournal of Neuroscience Research, 2008
- Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cellsJournal of Neurochemistry, 2008
- The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activityExperimental Cell Research, 2007
- LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activityBiochemical Journal, 2007
- Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutantsJournal of Neurochemistry, 2007
- Genetic screening for a single common LRRK2 mutation in familial Parkinson's diseaseThe Lancet, 2005
- Autophosphorylation kinetics of protein kinasesBiochemical Journal, 2002